Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of relugolix in adult hormone-sensitive advanced prostate cancer
CTR20262785Phase 3Active
- Sponsor
- Hangzhou Minsheng Pharmaceutical Group
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in prostate adenocarcinoma, prostate cancer (PCa), sponsored by Hangzhou Minsheng Pharmaceutical Group. Started Aug 2026; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20262785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262785.